Search Press releases Keywords From To 12 Apr 2024 UCB presents new data highlighting developments across expansive neurology portfolio at 76th American Academy of Neurology (AAN) Annual Meeting Read More 11 Apr 2024 Transparency notification FMR LLC Read More 5 Apr 2024 Acquisition of own shares Read More 4 Apr 2024 FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations Read More 29 Mar 2024 Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees Read More 22 Mar 2024 UCB receives positive CHMP opinion for BIMZELX[®]▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa Read More Pagination First page Previous page Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
